News
2don MSN
Dr Vinay Prasad, the FDA's Chief Medical and Scientific Officer, resigned from his post on 29 July 2025 after mounting ...
But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...
Loomer had slammed Prasad for allegedly denying drug approvals for rare diseases, and for his past support of left-leaning figures like Senator Bernie Sanders ...
2d
GlobalData on MSNPrasad’s FDA exit may accelerate cell and gene therapy approvalsVinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), ...
Such appeasement efforts proved insufficient to protect him from rival forces in the Republican Party, if not also in the ...
Sources also say that the administration plans to split CBER in two, with one of the section focused entirely on vaccines.
Prasad came to the Food & Drug Administration in May, hoping to set high, evidence-based standards for new medicines. He didn't even last three months. The industry's power has never been clearer.
Tidmarsh will temporarily guide CBER’s regulatory activities while the FDA searches for a permanent department lead.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results